Text Size
47 studies found for:    " January 05, 2011":" February 04, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Not yet recruiting The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals
Conditions: Acute Hepatitis C;   HIV Infections
Intervention:
2 Recruiting Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
Conditions: HIV Infection;   Hepatitis C
Interventions: Drug: Anti-HIV Agents;   Drug: raltegravir;   Drug: Emtricitabine and tenofovir disoproxil fumarate
3 Unknown † Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV
Conditions: MSM;   HIV Infections;   Risky Behaviors
Intervention:
4 Completed Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine
Condition: HIV Infections
Intervention: Biological: CN54gp140 glycoprotein-hsp70 conjugate vaccine
5 Unknown † Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
Conditions: HIV Infections;   Liver Toxicity;   Hepatitis Co-infection
Intervention:
6 Completed The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
Condition: HIV Infection
Intervention: Drug: Efavirenz
7 Completed Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.
Condition: HIV Infection
Intervention: Drug: TMC278LA
8 Completed Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM)
Conditions: HIV Infections;   Episodic Substance Use
Interventions: Behavioral: Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC);   Behavioral: Standard HIV testing with information only
9 Completed TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir
Condition: HIV Infections
Interventions: Drug: TMC278;   Drug: Raltegravir
10 Unknown † Ethnicity Data in HIV Positive Men Who Have Sex With Men
Condition: HIV Infections
Intervention:
11 Completed The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
Condition: HIV Infection
Intervention: Drug: Efavirenz
12 Recruiting Lenalidomide in Kaposi Disease Associated With HIV Infection
Condition: HIV Infection Associated Kaposi Disease
Intervention: Drug: Lenalidomide
13 Unknown † Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects
Condition: HIV Infection
Intervention: Biological: Hepavax-Gene
14 Completed Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
Conditions: HIV Infections;   HCV Infections
Interventions: Drug: boceprevir;   Drug: raltegravir
15 Recruiting Assessment of Normal Value of Acoustic Radiation Force Impulse (ARFI) Elastography in HIV Patients
Condition: HIV Infection
Intervention: Device: Acoustic radiation force impulse imaging
16 Completed Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients
Conditions: Flat Warts (Diagnosis);   HIV Infections
Intervention: Drug: Glycolic acid
17 Completed
Has Results 		Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
Condition: HIV-1 Infection
Intervention: Drug: FTC/RPV/TDF
18 Unknown † Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
Condition: HIV-1 Infection
Intervention: Drug: Disulfiram
19 Completed Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis
Conditions: Human Immunodeficiency Virus;   Hepatitis C
Intervention: Drug: Raltegravir 400 mg/12hours
20 Suspended A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
Condition: Human Immunodeficiency Virus I Infection
Interventions: Drug: GSK1349572;   Drug: GSK2248761
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years